EUVIMEDEUVIMED entdecken
Crossref

Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation

Francis G Wade iD, Krista L Lentine iD, David Turk iD, Kyleigh Kirbach iD, Taylor Knobloch iD, Mark Schnitzler iD, Kamran Qureshi iD, Wing-Kin Syn iD, Vidya A Fleetwood iD

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Francis G Wade und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Department of Internal Medicine, SSM Health/Saint Louis University, St. Louis, Missouri, USA. Hauptthemen laut MEDLINE: Waiting Lists, Kidney Transplantation, Glucagon-Like Peptides, Weight Loss. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation and National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Semaglutide, a glucagon‐like peptide‐1 receptor agonist, has demonstrated efficacy for weight loss and glycemic control in patients with obesity and type 2 diabetes mellitus, but data are limited for patients with end‐stage kidney disease on dialysis. We examined the weight loss efficacy and safety of semaglutide when prescribed to patients on dialysis to improve transplant candidacy and activation status. We conducted a retrospective chart review of 36 patients on dialysis who were prescribed semaglutide through a metabolic clinic between September 2021 and December 2023. Outcomes included weight loss efficacy, safety, and change in waitlist status at 1 year. Patients achieved a mean total body weight loss of 7.8% (SD 6.1). Of patients who were ineligible for transplant due to elevated body mass index, 48.2% achieved waitlist activation after successful weight loss. Treatment‐limiting gastrointestinal side effects occurred in 16.7% of patients. Patients on peritoneal dialysis (PD, 30.8%) versus hemodialysis (8.7%) discontinued therapy more frequently. In a single‐center cohort, patients who received semaglutide experienced significantly greater weight loss and increased rates of waitlist activation compared with a lifestyle‐only intervention. Semaglutide was generally well‐tolerated. Prospective studies should examine whether patients on PD experience severe GI side effects more frequently on semaglutide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waiting ListsKidney TransplantationGlucagon-Like PeptidesWeight LossRenal DialysisKidney Failure, ChronicObesityHypoglycemic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedFollow-Up StudiesPrognosisRisk FactorsAdultDiabetes Mellitus, Type 2AgedGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

diabetes mellitusglucagon‐like peptide 1 receptor agonistkidney transplantationobesitypatient selectionrenal dialysissemaglutide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Division of General Internal Medicine, Department of Internal Medicine, SSM Health/Saint Louis University, St. Louis, Missouri, USA.
  • SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University, St. Louis, Missouri, USA.
  • School of Medicine, Saint Louis University, St. Louis, Missouri, USA.
  • Department of Nutrition & Dietetics, SSM Health Saint Louis University Hospital, St. Louis, Missouri, USA.
  • Division of Gastroenterology & Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA.
  • Department of Physiology, Faculty of Medicine and Nursing, University of Basque Country, UPV/EHU, Vizcaya, Spain.

ORCID-Profile: Francis G Wade, Krista L Lentine, David Turk, Kyleigh Kirbach, Taylor Knobloch, Mark Schnitzler, Kamran Qureshi, Wing-Kin Syn, Vidya A Fleetwood

Förderung

  • Mid-America Transplant/Jane A. Beckman Endowed Chair in Transplantation and National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Wade, F. G., Lentine, K. L., Turk, D., Kirbach, K., Knobloch, T., Schnitzler, M., Qureshi, K., Syn, W. K., & Fleetwood, V. A. (2025). Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation. Clinical Transplantation. https://doi.org/10.1111/ctr.70344

Vancouver

Wade FG, Lentine KL, Turk D, Kirbach K, Knobloch T, Schnitzler M, et al. Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation. Clinical Transplantation. 2025. doi:10.1111/ctr.70344

BibTeX
@article{Wade2025,
  author = {Wade, Francis G and Lentine, Krista L and Turk, David and Kirbach, Kyleigh and Knobloch, Taylor and Schnitzler, Mark and Qureshi, Kamran and Syn, Wing-Kin and Fleetwood, Vidya A},
  title = {Bridging the Gap to Waitlist Activation: Semaglutide's Weight Loss Efficacy and Safety in Patients With Obesity on Dialysis Seeking Kidney Transplantation},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70344}
}
Kostenlos starten →